Alexandra S. Zimmer, MD


The Promise of Olaparib for the Treatment of HER2-Negative Breast Cancer

Alexandra S. Zimmer, MD, staff clinician, Women's Malignancies Branch, National Cancer Institute Center for Cancer Research, discusses the promising data seen thus far with olaparib (Lynparza) for the treatment of HER2-negative breast cancer.

Alexandria Phan, MD


The Importance of the Approval of Lanreotide and its Known Side Effects

Alexandria Phan, MD, discusses the importance of the approval of lanreotide for unresectable, well or moderately differentiated, locally advanced or metastatic GEP-NETs.

Alexey V. Danilov, MD, PhD


Questions Remain When Treating Patients With CLL

Alexey Danilov, MD, PhD, explains the unmet needs for patients with relapsed/refractory chronic lymphocytic leukemia.

Alfred L. Garfall, MD, MS


Patterns of Response and Resistance Among Hematologic Malignancies

Alfred L. Garfall, MD, MS, assistant professor of Medicine, the Hospital of the University of Pennsylvania, discusses patterns of response and resistance among hematologic malignancies.

Ali Maawy, MD


Immune Checkpoint Inhibitors in CRC

Ali Maawy, MD, and Patrick M. Boland, MD, provide a brief review of the immune environment of colorectal cancer (CRC) and recently reported studies of immunotherapy in CRC.

Ali McBride, PharmD, MS, BCOP


The Importance of the ACCC's Focus on Compensation With Ali McBride as President

Ali McBride, PharmD, MS, BCOP, discussed during the recent National Oncology Conference his goals for ACCC while serving as president, which include focusing on education, innovation, and compensation.<br /> &nbsp;

Alice Goodman


Metastatic Hormone-Sensitive Prostate Cancer Should Include Docetaxel Alongside ADT

Treatment initiation for hormone-sensitive metastatic prostate cancer should include the addition of docetaxel to androgen deprivation therapy (ADT) as standard of care.

Alice Shaw, MD, PhD


Efficacy Results for Lorlatinib in Patients With ALK-Positive NSCLC

Alice Shaw, MD, PhD, director of Thoracic Oncology at Massachusetts General Hospital, discussed the efficacy results from a recent trial investigating lorlatinib as treatment for patients with anaplastic lymphoma kinase-positive (ALK) non&ndash;small cell lung cancer that had failed other treatments prior, including crizotinib (Xalkori) and other multiple ALK tyrosine-kinase inhibitors.

Alice T. Shaw, MD, PhD


Phase III Results for Alectinib Compared With Crizotinib in ALK+ Metastatic NSCLC

Alice T. Shaw, MD, PhD, director, thoracic oncology, Massachusetts General Hospital, discusses results of the phase III clinical trial comparing alectinib (Alecensa) versus crizotinib (Xalkori) in first-line treatment for ALK-positive, advanced non&ndash;small cell lung cancer.

Alicia K. Morgans, MD, MPH


First Real-World Data on Second-Generation AR Inhibitor Use in nmCRPC

A review of real-world data from the DEAR study of darolutamide, enzalutamide and apalutamide for the treatment of nonmetastatic castration-resistant prostate cancer is given by Alicia Morgans, MD, MPH.

Allie Casey


Study Finds Link Between E-Cigarette Use and Bladder Cancer

Findings from a recent pilot study done at the University of Pittsburgh Medical Center showed a potential link between e-cigarette use and bladder cancer.

Allie Strickler


Concomitant Chemoradiotherapy Demonstrates Survival Benefit in Nasopharyngeal Carcinoma

The addition of chemotherapy, either adjuvant or induction, to concomitant chemoradiotherapy (CRT) achieved a significantly high survival benefit for patients with locally advanced nasopharyngeal carcinoma.

Allison W. Kurian, MD, MSc


The Importance of Multi-Gene Panel Testing for BRCA Mutations

Allison W. Kurian, MD, MSc, associate professor of Medicine and of Health Research and Policy, Stanford University School of Medicine, discusses two ongoing trials utilizing multi-gene panels to uncover previously undetected risks in patients with breast and ovarian cancer.

Allyson Perry


Renal Complications Need Consideration in CIBD

Bisphosphonates and denosumab are bone-modifying agents that prevent or delay cancer-induced bone disease and skeletal-related events by inhibiting bone resorption.

Alok Khorana, MD


Dr. Khorana Discusses Long-Term Tinzaparin Versus Warfarin in the CATCH Study

Alok Khorana, MD, discusses the long-term impacts of tinzaparin versus warfarin, as well as clinical predictors of recurrent venous thromboembolism (VTE) in cancer patients, in the CATCH study.

Alon Altman, MD


Neoadjuvant Chemotherapy for Patients With High-Grade Endometrial Cancer

Alon Altman, MD, associate professor, Department of Obstertrics, Gynecology and Reproductive Sciences, University of Manitoba, discusses neoadjuvant chemotherapy for patients with high-grade serous carcinoma. Across the world, many centers have shifted to more patients receiving neoadjuvant chemotherapy followed by surgery and further chemotherapy.

Amanda L. Kong, MD, MS, FACS


Dr. Amanda Kong on High Versus Low Volume Hospitals in the Treatment of Breast Cancer

&#8203;Amanda L. Kong, MD, MS, FACS, discusses breast cancer care at high volume hospitals versus low volume hospitals. Kong says the study is the first one that looks at processes as a bundle and takes into account socioeconomic statuses of patients.

Amanda Przespolewski, DO


Chimeric Antigen Receptor T-Cell Therapy in Acute Myeloid Leukemia

Although preclinical data are promising, there are many clinical challenges in developing CAR T-cell therapy in acute myeloid leukemia.

Amanda Ramos, MD


Exploring Checkpoint Inhibition in Endometrial Cancers

Amanda Ramos, MD, a first-year fellow at the Massachusetts General Hospital in Boston, discusses the future potential of checkpoint inhibition therapy in the treatment of patients with recurrent endometrial cancers.

Ami V. Desai, MD, MSCE


Treatment Options for Relapsed/Refractory Solid Tumors in Pediatric and Young Adult Patients

Ami V. Desai, MD, MSCE, assistant professor of Pediatrics at the University of Chicago Medicine Comer Children&rsquo;s Hospital, discusses the current treatment landscape for pediatric and young adult patients with relapsed/refractory solid tumors.

Amit Singal, MD


Case 4: Later Lines of Therapy for Patients With Recurrent HCC

Expert panelists consider later-line treatment options for a patient with recurrent hepatocellular carcinoma.

Amitabh Chak, MD, MS


Dr. Amitabh Chak on New Screening Methods for Esophageal Cancer

Amitabh Chak, MD, MS, professor of Medicine, director, Clinical Research, Division of Gastroenterolgy Diseases, Case Western Reserve University, discusses advances in esophageal cancer. Chak says some of the more "exciting" developments in the treatment of the disease are transnasal endoscopy, as well as a new type of screening device that acts as a "pap smear" for the esophagus.

Amol K. Narang, MD


Unanswered Questions Remain Regarding SBRT in Gastrointestinal Cancers

Amol K. Narang, MD, discusses the unanswered questions that still need to be addressed to further expand the role of stereotactic body radiation therapy in gastrointestinal cancers.

Amro Elshoury, MBChB


Optimizing FLT3 Inhibitor Monotherapy in Acute Myeloid Leukemia

Acute myeloid leukemia (AML) therapy is guided mainly by cytogenetic profile, such as chromosomal duplication or deletion, and molecular mutations. <em>FLT3</em> mutations are the most common genetic abnormalities detected in patients with AML and are usually associated with a high relapse rate and short overall survival. Given the dismal outcomes in patients with <em>FLT3</em>-mutant AML, a great effort has been underway over the last several years to develop clinically effective FLT3 inhibitors.

Amy Heimberger, MD


Dr. Amy Heimberger on Better Imaging and Combination Therapies in Glioblastoma

Heimberger says the treatment paradigm's future is two-pronged, in that it will consist of both combination therapies that activate the immune system and prevent immunosuppression, as well as understand CT and MRI scans of brain cancer patients.

Amy Heimburger, MD


Dr. Amy Heimberger on Immunotherapeutics in the Context of Glioblastoma

Amy Heimberger, MD, professor in the Department of Neurosurgery, University of Texas MD Anderson Cancer Center, talks about immunotheraputics in the context of glioblastoma (GBM).